Pregnancy. If a woman has been confirmed as pregnant she will not be eligible to take part in the trial. If she suspects there is a chance that she may be pregnant, a pregnancy test should be undertaken; however, a pregnancy test for all women of child-bearing potential is not mandatory Negative serum pregnancy test in women of child-bearing potential within days of day (D) of treatment Refusal to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential Women of child bearing potential must have a negative serum pregnancy test result within days prior to initiation of study drug Negative pregnancy test for women of child bearing potential Negative serum pregnancy test and using medically acceptable form of contraception if of child bearing potential Negative serum or urine pregnancy test within days prior to the first dose of ALRN- for women of child-bearing potential Negative pregnancy test in women of child bearing potential Negative urine or serum pregnancy test performed =< days prior to registration, for women of child bearing potential only Negative pregnancy test in women of child-bearing potential Negative pregnancy test for women of child bearing potential Pregnant women are excluded from this study; breastfeeding women are also excluded; female subjects of child bearing potential must have a negative serum pregnancy test obtained prior to trial registration Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within days prior to randomization. Women of child-bearing potential has negative pregnancy test prior to initiating study drug dosing Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus. Women of child-bearing potential must have a negative pregnancy test Negative serum or urine pregnancy test for women with child-bearing potential Pregnancy (positive pregnancy test) or lactation. Use of effective means of contraception (men and women) in subjects of child-bearing potential Women of child-bearing potential (WOCBP) must have a negative pregnancy test within days before study enrollment Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception Subjects who are pregnant or planning to become pregnant during the study; women of child bearing potential must have a negative pregnancy test A negative pregnancy test will be required for all women of child bearing potential; breast feeding is not permitted Women of child-bearing potential must have a negative pregnancy test within week of IORT treatment CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: For women of child-bearing potential, a negative serum pregnancy testing will be verified within days prior to treatment Pregnant or lactating women; women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within days prior to start of study drug Women of child-bearing potential must have a negative pregnancy test; women of child-bearing potential are defined as all women who are not post-menopausal or who have not had a hysterectomy; postmenopausal will be defined as women over the age of who have not had a menstrual period in at least year Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential without a serum negative pregnancy test and not willing to refrain from sexual activity or to utilize an adeguate contraceptive methods during all the course of the study Negative pregnancy test for women of child bearing potential Women of child-bearing potential has negative pregnancy test within hours of initiating study drug dosing Women of child-bearing potential must have a negative pregnancy test or fewer days from registration Negative pregnancy test in women of child-bearing potential (For both cohorts A and B): Women of child-hearing potential (WCBP) must have a negative pregnancy test within days prior to the first dose of study treatment Negative serum pregnancy test within days of day (D) of treatment in women of child bearing potential Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test at screening Pregnant or breastfeeding - women of child bearing potential must have a negative pregnancy test at screening Women who are pregnant or breast feeding; a pregnancy test will be administered to women of child bearing potential (per institutional policies) at screening; women must agree to pregnancy tests prior to (up to calendar day) each administration of a radionuclidic agent, including tracer doses, to be considered for this study Obtained =< days prior to registration: Negative pregnancy test for persons of child-bearing potential Negative pregnancy test for women of child-bearing potential within hours prior to first dose of BMX-. Women of child-bearing potential must have a negative serum or urine pregnancy test. Women of child bearing potential must have a negative urine or blood pregnancy test within days of study enrollment Women must not be pregnant or breast-feeding\r\n* All female patients of child-bearing potential must have a negative serum pregnancy test within weeks prior to treatment to rule out pregnancy \r\n* Pregnancy testing is not required for post-menopausal or surgically sterilized women Women of child bearing potential: positive pregnancy test (serum) Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus Women of child bearing potential must have a negative pregnancy test; women of child-bearing potential are defined as all women except women who are post-menopausal or who have had a hysterectomy; postmenopausal will be defined as women over the age of who have not had a menstrual period in at least year Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential (WOCBP) must have a negative pregnancy test Women of child-bearing potential must have a negative urinary or serum pregnancy test Negative pregnancy test for women with child-bearing potential Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of each dose of JTX- Negative pregnancy test for women of child bearing potential Women of child bearing potential must have a negative pregnancy test by urinalysis Women of child?bearing potential (e.g. not post?menopausal or permanently sterilized women) must have a negative pregnancy test obtained within days prior to registration; this is to prevent potential harm to the fetus by glyburide and radiotherapy Women of child-bearing potential must have negative pregnancy test prior to initiating study drug treatment Women of child-bearing potential must have a negative pregnancy test Pregnant or lactating women of child bearing potential must have a negative pregnancy test within days of study treatment start Women of child-bearing potential (WOCBP) must have a negative pregnancy test within days of registration; urine human gonadotropin (HCG) is an acceptable pregnancy assessment Women of child-bearing potential must have a negative serum pregnancy test =< hours prior to initiating treatment Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. Women of child-bearing potential must have a negative pregnancy test at screening Women of child-bearing potential must have a negative pregnancy test For women of child-bearing potential, negative pregnancy test within days prior to starting treatment Pregnancy (positive pregnancy test) or lactation; use of effective means of contraception (men and women) in subjects of child-bearing potential Women of child-bearing potential must have a negative pregnancy test Women of child bearing potential only: Negative urine or serum pregnancy test Women of child-bearing potential must have a negative pregnancy test Pregnant or breast-feeding; urine pregnancy test will be assessed at the baseline visit in women of child-bearing potential with chronic pain Negative pregnancy test for women of child-bearing potential For women of child-bearing potential, negative serum pregnancy test within days prior to registration Subjects of child bearing potential must have a negative urine pregnancy test within days prior to first dose of the study drug Current or planned pregnancy or lactation in women of child bearing age (confirmed by negative pregnancy test prior to start of therapy) Patients must not be pregnant; women of child-bearing potential must also have a negative pregnancy test within weeks prior to start of protocol therapy (radiation and veliparib) Negative pregnancy test (serum or urine) for women of child bearing potential; all protocol participants must agree to adequate contraception Women of child-bearing potential must have a negative pregnancy test Breast-feeding or pregnant; serum pregnancy test for women of child-bearing potential must be performed within days prior to first dose of study treatment Negative serum pregnancy test for women of child-bearing potential Negative pregnancy test for women of child-bearing age Women of child bearing age must be using adequate birth control and have a negative pregnancy test Women of child-bearing age must be using adequate birth control and have a negative pregnancy test Pregnant women are excluded; therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period Patients who are pregnant; negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is required during the study period Child bearing age women with positive pregnancy test Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening Women of child-bearing potential must have a negative serum pregnancy test within days prior to first dose of abemaciclib Negative pregnancy test in women of child bearing potential Negative serum pregnancy test result in women of child-bearing potential (WOCBP) Negative pregnancy test for women with child-bearing potential Negative pregnancy test for women of child bearing potential All women of child-bearing potential who take ribavirin will need to have a negative pregnancy test Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least mIU/mL within days and again within hours prior to beginning study treatment Women of child bearing potential must have a negative pregnancy test Pregnant or lactating women of child bearing potential must have a negative pregnancy test within days of study treatment start Women of child-bearing potential must have a negative pregnancy test For women of child bearing potential, a negative serum pregnancy testing will be verified within days prior to pre chemotherapy apheresis Women must: have a negative serum or urine pregnancy test within days prior to study entry if she is a woman of child-bearing potential (WOCBP), or be at least one year post-menopausal, OR be surgically sterile Negative pregnancy test (serum or urine) within days of registration in women of child-bearing potential Negative pregnancy test for women of child bearing potential Women of child-bearing potential must have a negative serum pregnancy test within days prior to randomization In women of child-bearing potential, negative serum pregnancy test within days of the first infusion of G- Woman of child-bearing potential has negative pregnancy test before the initiation of study drug dosing Women of child bearing potential must have a negative serum pregnancy test. For women of child-bearing potential, a negative urine pregnancy test Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative Pregnant and nursing women are excluded; men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least months after completing therapy; women with child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening A negative pregnancy test will be required for all women of child bearing potential; breast feeding is not permitted Negative serum pregnancy test for women of child-bearing potential Patients with child-bearing potential must have a negative urine pregnancy test within days prior to registration A negative serum pregnancy test obtained within weeks prior to the start of treatment in all women of child-bearing potential Women of child-bearing potential must have a negative (urine or blood) pregnancy test within weeks prior to start of protocol therapy; women of child-bearing potential must also use effective non-hormonal contraception while undergoing radiation therapy Negative pregnancy test for women with child-bearing potential Patients must not be pregnant (positive pregnancy test) or breast feeding; pregnancy test must be done within days prior to registration; effective contraception (men and women) must be used in patients of child-bearing potential while on study treatment and for months after Patient refuses to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential In women of child-bearing potential, negative serum pregnancy test within hours prior to day of study treatment and agree to use effective contraception Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; women of child bearing potential must undergo pregnancy testing prior to each dose if the previous pregnancy test was greater than days prior and a pregnancy test at months after the last dose Women of child bearing potential must undergo pregnancy testing within days of the first dose of study therapy; women must also undergo pregnancy test at months after the last dose Woman of child-bearing potential has negative pregnancy test before the initiation of study drug dosing Negative urine pregnancy test within one week before starting treatment in women of child-bearing potential Women must:\r\n* Have a negative serum or urine pregnancy test within days prior to study entry if she is a woman of child-bearing potential, OR\r\n* Be at least one year post-menopausal, OR\r\n* Be surgically sterile Negative pregnancy test in women of child-bearing potential Pregnancy (positive pregnancy test) or lactation- breast feeding; lack of effective means of contraception (men and women) in subjects of child-bearing potential Pregnancy (positive pregnancy test) or lactation; (an effective means of contraception [men and women] in subjects of child-bearing potential must be used) Women of child-bearing potential must have a negative pregnancy test Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test within days of study treatment start Negative urine or serum pregnancy test done =< days prior to randomization, for women of child bearing potential only Women of child bearing potential must have a negative pregnancy test Pregnancy in women of child bearing potential (pregnancy test performed within weeks of study entry) Women of child bearing potential having a positive urine or serum pregnancy test (hCG) at the time of pre-operative evaluation (within days of surgery) Pregnant women are excluded for fear of danger to the fetus; therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is required during the study period Women of child-bearing potential must have a negative pregnancy test Subjects who are women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at Day . Negative serum pregnancy test for women of child-bearing potential Negative pregnancy test for women of child-bearing potential. Women of child bearing potential must have a negative pregnancy test and use reliable methods of contraception Patients with child bearing potential must have a negative pregnancy test (urine or serum) prior to study treatment Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential will be required to undergo a negative pregnancy test prior to enrollment, and women who are currently pregnant will not be considered eligible Women of child-bearing age must have a negative, quantitative serum pregnancy test =< days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation) Women of child-bearing age must have a negative pregnancy test Women of child bearing potential must have a negative serum pregnancy test For women of child-bearing potential, negative pregnancy test within days prior to starting treatment Pregnant or lactating women. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within hours prior to starting study drug or a urine pregnancy test shall be done on Day of Cycle Women of child bearing potential must have a negative pregnancy test Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within days prior to randomization. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. Positive pregnancy test in women of child-bearing potential. Serum pregnancy test for women of child bearing potential must be negative at entry into study Women of child-bearing potential must have a negative pregnancy test within days prior to commencement of study treatment Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test. Negative pregnancy test (urinary or serum beta-HCG) at screening (applicable to women of child bearing potential who are sexually active) Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative Women of child-bearing potential must have a negative pregnancy test within days prior to the first dose of study treatment. Women of child-bearing potential must have a negative pregnancy test Women of child-bearing potential must have a negative pregnancy test For women of child-bearing potential, negative serum pregnancy test within days prior to registration Women of child-bearing potential must have a negative pregnancy test prior to initiating study treatment Women of child bearing potential between the ages of and years of age must have a negative urine pregnancy test prior to undergoing simulation in preparation for radiation therapy to the pelvis Pregnancy (positive pregnancy test) or lactation; use of effective means of contraception (men and women) in subjects of child-bearing potential Women of child bearing potential with a negative urine or blood pregnancy test within a month of enrollment (only for patients who are going to be randomized to either therapeutic arms) Women of child-bearing age must have a negative, quantitative serum pregnancy test =< days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation) Pregnant or nursing women - women of child?bearing potential must have negative serum or urine pregnancy test Pregnancy or lactation; negative pregnancy test is required within the screening window for women of child bearing potential Women of child-bearing potential must have a confirmed negative pregnancy test result prior to enrollment Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test at screening Negative urine pregnancy test within weeks of registration for women of child-bearing potential; women of child-bearing potential must have a documented negative pregnancy test and agree to use adequate contraception throughout the study period Women of child-bearing potential must have a negative pregnancy test within one week of IORT treatment Negative serum pregnancy test, if of child-bearing potential Negative serum pregnancy test for women of child bearing potential (WOCBP) Women of child-bearing potential must have a negative urinary or serum pregnancy test within days of baseline imaging Women of child bearing potential must have a negative serum pregnancy test PATIENT: If of child-bearing potential, must have a negative pregnancy test Women of child bearing potential with negative pregnancy test documented Negative pregnancy test for women of child-bearing potential Negative urine pregnancy test in women of child-bearing potential Women of child-bearing potential must have a negative blood pregnancy test at screening and use an adequate and medically acceptable contraceptive method. Negative serum pregnancy test for women of child bearing potential Women of child bearing potential must have a negative serum pregnancy test no more than hours prior to registration Negative urine pregnancy test in women of child-bearing potential (WCBP) within week prior to s-DCT Negative pregnancy test if of child-bearing age Women of child-bearing age will be asked to undergo a pregnancy test prior to enrollment Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential Patients of child-bearing potential must have a negative urine or serum pregnancy test Women who are not of child-bearing potential, and women of child-bearing potential who agree to use adequate contraceptive measures during the study and for days after the last dose of study medication, and who have a negative serum or urine pregnancy test within week prior to initial trial treatment.